Iperion (NZSE:IPR) EPS without NRI: NZ$0.00 (TTM As of Sep. 2025)


What is Iperion EPS without NRI?

Iperion NZSE:IPR EPS without NRI is NZ$0.00 as of Sep. 2025. The stock has 2 warning signs investors should review.

Iperion's earnings per share without non-recurring items for the six months ended in Sep. 2025 was NZ$0.00. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2025 was NZ$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Iperion's EPS without NRI or its related term are showing as below:

During the past 12 years, Iperion's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 74.50% per year. The lowest was 74.50% per year. And the median was 74.50% per year.

NZSE:IPR's 3-Year EPS without NRI Growth Rate is not ranked *
in the Diversified Financial Services industry.
Industry Median: 19.4
* Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.

Iperion's EPS (Diluted) for the six months ended in Sep. 2025 was NZ$0.00. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 was NZ$0.00.

Iperion's EPS (Basic) for the six months ended in Sep. 2025 was NZ$0.00. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 was NZ$0.00.


Iperion  (NZSE:IPR) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Iperion EPS without NRI Related Terms


Iperion EPS without NRI Historical Data

* Premium members only.

The historical data trend for Iperion's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iperion EPS without NRI Chart

Iperion Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 -0.00 -0.00 -0.00

Iperion Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.00 -0.00 0.00 0.00 0.00

NZSE:IPR vs CCCX, CEPF, BCSS: EPS without NRI Comparison

For the Shell Companies subindustry, Iperion's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Iperion PE Ratio without NRI vs Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, Iperion's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Iperion's PE Ratio without NRI falls into.



Iperion EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NZ$0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS without NRI →
What does a EPS without NRI of NZ$0.00 mean?
Iperion (NZSE:IPR) has a EPS without NRI of NZ$0.00 as of Sep. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Iperion and its competitors.
Is Iperion's EPS without NRI too high?
Iperion's current EPS without NRI is NZ$0.00.
How does Iperion's EPS without NRI compare to CCCX and CEPF?
Iperion's EPS without NRI of NZ$0.00 can be compared against companies in the Diversified Financial Services industry. The industry median EPS without NRI is 19.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Diversified Financial Services company?
The median EPS without NRI among Diversified Financial Services companies is 19.40, based on 173 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Iperion and its competitors. For the Diversified Financial Services industry, the median EPS without NRI is 19.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Iperion's current EPS without NRI is NZ$0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iperion stock overvalued right now?
Iperion (NZSE:IPR) has a current EPS without NRI of NZ$0.00. The current EPS without NRI is NZ$0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Iperion (NZSE:IPR), the current EPS without NRI is NZ$0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iperion Business Description

Address c/o Duncan Cotterill, 50 Customhouse Quay, Level 5 Tower Building, Wellington, NTL, NZL, 6011
Iperion Ltd is engaged in the process of commercializing a novel antimicrobial coating product, being marketed under the name Pathoglaze. The company is engaged in manufacturing, selling, distributing, importing, and exporting a self-cleaning, transparent, antimicrobial surface coating product.